TrialThe Lancet. Oncology2025

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study.

Shilpa Gupta et al.PubMed ↗Publisher ↗

No numbers read from the abstract.